GLP-1 Key Research Facts Full name: Glucagon-Like Peptide-1 incretin hormone of the proglucagon family Primary bioactive form: GLP-1(736)amide 30 amino acids, C-terminally amidated Gene source: Proglucagon gene processed by PCSK1 in intestinal L-cells and brainstem NTS neurons In vivo half-life: Approximately 12 minutes rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide) Primary receptor: GLP-1R (GLP-1 receptor) class B G protein-coupled receptor (GPCR) Signalling: GLP-1R activation cAMP elevation PKA/CREB activation glucose-dependent insulin secretion Additional signalling: PI3K/Akt pathway -cell survival, proliferation, and glucose sensitivity Secretion pattern: Biphasic post-meal release from intestinal L-cells early neural/endocrine peak + late direct nutrient-contact peak Fasting plasma level: ~510 pmol/L

Eligible people can receive prescriptions for Food and Drug Administration (FDA)-approved GLP-1 medications, including: This includes new GLP-1 options such as the Wegovy pill, Zepbound KwikPen, and Foundayo
Tier 1 consists primarily of low-cost generic drugs, while the higher tiers contain brand-name drugs and specialty medications
Would she laugh or, worse, scold me
Oral alternatives Oral GLP-1 formulations are emerging as alternatives to injection